Antibody Responses to Fusobacterium nucleatum Proteins in Prediagnostic Blood Samples are not Associated with Risk of Developing Colorectal Cancer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Julia Butt, Faculty of Biosciences, University of Heidelberg, Germany., Tyskland
  • Mazda Jenab, Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France., Frankrig
  • Michael Pawlita, Infection and Cancer Epidemiology, Division of Molecular Diagnostics of Oncogenic Infections, German Cancer Research Center (DKFZ), Heidelberg, Germany., Tyskland
  • Kim Overvad
  • Anne Tjonneland, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.
  • ,
  • Anja Olsen
  • Marie-Christine Boutron-Ruault, Institut Gustave Roussy, Villejuif, France., Frankrig
  • Franck Carbonnel, Department of Gastroenterology, Bicêtre University Hospital, Assistance Publique des Hôpitaux de Paris, Le Kremlin Bicêtre, France., Frankrig
  • Francesca Romana Mancini, Institut Gustave Roussy, Villejuif, France., Frankrig
  • Rudolf Kaaks, Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. r.kaaks@dkfz-heidelberg.de., Tyskland
  • Tilman Kühn, Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. r.kaaks@dkfz-heidelberg.de., Tyskland
  • Heiner Boeing, Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany, karina.meidtner@dife.de., Tyskland
  • Antonia Trichopoulou, Hellenic Health Foundation, Athens, Greece; WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Greece., Grækenland
  • Anna Karakatsani, 2nd Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Haidari, Greece., Grækenland
  • Domenico Palli, Cancer Risk Factors and Life-Style Epidemiology Unit. Institute for Cancer Research, Prevention and Clinical Network - ISPRO, 50141, Florence, Italy., Italien
  • Valeria Maria Pala, Epidemiology and Prevention Unit, Department of Preventive & Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Italien
  • Rosario Tumino, Cancer Registry and Histopathology Department, "Civic M.P. Arezzo" Hospital, ASP, Ragusa, Italy., Italien
  • Carlotta Sacerdote, Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy., Italien
  • Salvatore Panico, Dipartimento die Medicina Clinica e Chirurgia, Federico II University, Naples, Italy., Italien
  • Bas Bueno-de-Mesquita, Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia., Malaysia
  • Carla H van Gils, Julius Center for Health Sciences and Primary Care, Cancer Epidemiology University Medical Center Utrecht, 3508 GA, Utrecht, The Netherlands., Holland
  • Roel C H Vermeulen, Division of Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands., Holland
  • Elisabete Weiderpass, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway., Norge
  • José Ramón Quirós, EPIC Asturias, Public Health Directorate, Asturias, 33006 Oviedo, Spain. joseramon.quirosgarcia@asturias.org., Spanien
  • Eric Jeffrey Duell, Unit of Nutrition and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. llujan@iconcologia.net., Spanien
  • Maria-Jose Sánchez, CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain., Spanien
  • Miren Dorronsoro, Public Health Direction and Biodonostia Research Institute CIBERESP, Basque Regional Health Department, San Sebastian, Spain., Spanien
  • José María Huerta, Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain., Spanien
  • Eva Ardanaz, Navarre Public Health Institute, Pamplona, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Spanien
  • Bethany Van Guelpen, Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden., Sverige
  • Sophia Harlid, Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden., Sverige
  • Aurora Perez-Cornago, Cancer Epidemiology Unit, Nuffield Department of Population Health University of Oxford, United Kingdom., Storbritannien
  • Marc J Gunter, Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France., Frankrig
  • Neil Murphy, Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France., Frankrig
  • Heinz Freisling, Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France., Frankrig
  • Dagfinn Aune, Department of Epidemiology and Biostatistics, , The School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG London, United Kingdom., Storbritannien
  • Tim Waterboer, Infection and Cancer Epidemiology, Division of Molecular Diagnostics of Oncogenic Infections, German Cancer Research Center (DKFZ), Heidelberg, Germany., Tyskland
  • David J Hughes, Cancer Biology and Therapeutics Group, UCD Conway Institute, School of Biomolecular and Biomedical Science, University College Dublin, D04 V1W8 Dublin, Ireland. david.hughes@ucd.ie., Irland

BACKGROUND: There is a lack of prospective data on the potential association of Fusobacterium nucleatum (F. nucleatum) and colorectal cancer risk. In this study, we assessed whether antibody responses to F. nucleatum are associated with colorectal cancer risk in prediagnostic serum samples in the European Prospective Investigation into Nutrition and Cancer (EPIC) cohort.

METHODS: We applied a multiplex serology assay to simultaneously measure antibody responses to 11 F. nucleatum antigens in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CI).

RESULTS: We observed neither a statistically significant colorectal cancer risk association for antibodies to individual F. nucleatum proteins nor for combined positivity to any of the 11 proteins (OR, 0.81; 95% CI, 0.62-1.06).

CONCLUSIONS: Antibody responses to F. nucleatum proteins in prediagnostic serum samples from a subset of colorectal cancer cases and matched controls within the EPIC study were not associated with colorectal cancer risk.

IMPACT: Our findings in prospectively ascertained serum samples contradict the existing literature on the association of F. nucleatum with colorectal cancer risk. Future prospective studies, specifically detecting F. nucleatum in stool or tissue biopsies, are needed to complement our findings.

OriginalsprogEngelsk
TidsskriftCancer Epidemiology, Biomarkers & Prevention
Vol/bind28
Nummer9
Sider (fra-til)1552-1555
Antal sider4
ISSN1055-9965
DOI
StatusUdgivet - sep. 2019

Bibliografisk note

©2019 American Association for Cancer Research.

Se relationer på Aarhus Universitet Citationsformater

ID: 164051457